| Literature DB >> 28507124 |
Pan F Chan1, Thomas Germe2, Benjamin D Bax3, Jianzhong Huang4, Reema K Thalji4, Eric Bacqué5, Anna Checchia6, Dongzhao Chen4, Haifeng Cui4, Xiao Ding4, Karen Ingraham4, Lynn McCloskey4, Kaushik Raha4, Velupillai Srikannathasan3, Anthony Maxwell2, Robert A Stavenger1.
Abstract
A paucity of novel acting antibacterials is in development to treat the rising threat of antimicrobial resistance, particularly in Gram-negative hospital pathogens, which has led to renewed efforts in antibiotic drug discovery. Fluoroquinolones are broad-spectrum antibacterials that target DNA gyrase by stabilizing DNA-cleavage complexes, but their clinical utility has been compromised by resistance. We have identified a class of antibacterial thiophenes that target DNA gyrase with a unique mechanism of action and have activity against a range of bacterial pathogens, including strains resistant to fluoroquinolones. Although fluoroquinolones stabilize double-stranded DNA breaks, the antibacterial thiophenes stabilize gyrase-mediated DNA-cleavage complexes in either one DNA strand or both DNA strands. X-ray crystallography of DNA gyrase-DNA complexes shows the compounds binding to a protein pocket between the winged helix domain and topoisomerase-primase domain, remote from the DNA. Mutations of conserved residues around this pocket affect activity of the thiophene inhibitors, consistent with allosteric inhibition of DNA gyrase. This druggable pocket provides potentially complementary opportunities for targeting bacterial topoisomerases for antibiotic development.Entities:
Keywords: antibiotic; drug discovery; topoisomerase
Mesh:
Substances:
Year: 2017 PMID: 28507124 PMCID: PMC5465892 DOI: 10.1073/pnas.1700721114
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205